// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

MLL genomic DNA Breakpoints In Infant Acute Leukemia

Grigory Tsaur - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Low Expression Of BCL11B Predicts Poor Overall Survival In Adult Standard Risk T-ALL

Isabelle Bartram - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Defining Functional Heterogeneity In Acute Lymphoblastic Leukemia

Stephanie M. Dobson - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Acute lymphoblastic leukemia

N/A

Prognostic Significance Of CRLF2 Over-Expression In Pediatric Acute Lymphoblastic Leukemia

Mio Yano - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach

Roger Belizaire - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Genetic and Epigenetic Profile Of Early Relapsed Childhood ALL

Yucel Erbilgin - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Minimal Residual Disease Monitoring In Acute Lymphoblastic Leukemia Patients Using Immune Receptor Sequencing

Malek Faham - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing Retrospective Review Of The SWOG Experience

Min Fang - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Role Of Day-15 Peripheral Blood MRD Assessment In Pediatric B-ALL Patients

Karthik B.K Bommannan - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Accumulation Of Gene Alterations Of TP53, Crebbp and IKZF1 Is a Prognostic Factor In Adult Acute Lymphoblastic Leukemia

Kenji Tokunaga - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

TP53

Genomic Heterogeneity In Pediatric Acute Lymphoblastic Leukemia

Isaac Yaniv - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Acute lymphoblastic leukemia

N/A

Molecular Basis Of Minimal Residual Disease In Subtypes Of Pediatric B Cell Acute Lymphoblastic Leukemia

Jitsuda Sitthi-Amorn - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

TP53

Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Katherine Sutherland - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Mycophenolate mofetil

The Regulation Of Central Nervous System Acute Lymphoblastic Leukemia By Natural Killer Cells

Liron Frishman-Levy - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

IL-15

Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study

Clara Mariette - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

amphotericin b cholesteryl sulfate complex Intravenous

Young Paternal Age and Risk Of Infant Acute Lymphoblastic Leukemia

Julie A. Ross - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

N/A

Natural Killer Cells In Pediatric Acute Lymphoblastic Leukemia Patients At Diagnosis Demonstrate An Inhibitory Phenotype and Reduced Cytolytic Capacity

Rayne H. Rouce - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

lonomycin

Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia

Geoffrey L. Uy - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL)

Michael E. Rytting - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

Change In Albumin Levels During Induction Predicts Survival Outcomes In Adult Acute Lymphoblastic Leukemia

Kimberly Komatsubara - American Society of Hematology (ASH) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

PEG-asparaginase

Copyright © 2026. QuantiNova All rights reserved